CMED Opens Directed Consultation on Pricing of Advanced Therapies
QR Group analyzes regulatory impacts and what companies need to consider in the commercialization of gene, cell and tissue therapies The Drug Market Regulation Chamber (CMED) has started a targeted consultation on the pricing of advanced therapies — such as gene, cell, and tissue therapies. The measure aims to receive contributions from the regulated sector, […]
